- Financial Times•3 hours ago
Drugmaker AstraZeneca's US-listed shares fell 4 per cent on Thursday after it announced that US regulators had dealt a setback to its prospective cancer drug durvalumab by placing a temporary halt on enrolling ...
- The Wall Street Journal•3 hours ago
AstraZeneca PLC said it had suspended enrollment into two large clinical trials on head and neck cancer while it investigates whether the treatment is causing patients to bleed.
- Financial Times•4 hours ago
AstraZeneca was a faller on Thursday on news it had suspended a trial of one of its most important pipeline drugs. Filings on clinicaltrials.gov, the US National Library of Medicine's public registry, ...
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
|Bid||4,500.00 x 6100|
|Ask||5,100.00 x 13000|
|Day's Range||4,502.00 - 4,956.64|
|52wk Range||3,680.00 - 5,505.00|
|1y Target Est||N/A|
|P/E Ratio (ttm)||26.37|
|Avg Vol (3m)||2,579,925|
|Dividend & Yield||N/A (N/A)|